FDA scientists resist HHS plan to relax enforcement on wellness peptides
Solo los hechos

FDA scientists resist HHS plan to relax enforcement on wellness peptides

Resumen

Most FDA scientific staff opposed a Health and Human Services proposal that would limit enforcement against specialty pharmacies selling unapproved peptide drugs, citing safety concerns.

The U.S. Department of Health and Human Services (HHS) released a draft policy that would direct the Food and Drug Administration (FDA) not to enforce certain rules against specialty pharmacies that compound a small group of injectable peptides marketed for muscle building, injury recovery and energy enhancement. The peptides, including BPH-157, TB-500 and KPV, have not undergone the FDA’s standard review for safety and efficacy and are currently classified as illegal drugs under existing regulations.

According to six officials familiar with the policy’s development, the majority of FDA scientific staff voiced strong objections, warning that the approach could undermine the agency’s mission to keep unproven health products off the market. While HHS officials initially sought a formal regulation that would list the peptides as safe for compounding, they later shifted to a strategy that merely instructs the FDA not to enforce existing rules.

FDA scientists contributed technical input, recommending safeguards such as requiring peptide ingredients to be sourced from FDA-registered manufacturers, collecting side-effect data, and verifying chemical identity. These measures were incorporated into the final HHS draft.

Health Secretary Robert F. Kennedy Jr., a self-described “big fan” of peptides, has advocated for broader access, arguing that Americans are turning to imported products marketed as “research use only.” The FDA, however, has warned about the risks of unapproved peptides, adding several to a list of substances that should not be compounded due to potential allergic reactions, kidney damage and tumor growth.

The proposal marks an unusual instance of HHS leading policy development in an area traditionally overseen by the FDA, which maintains an office dedicated to protecting consumers from unsafe compounded drugs. The agency’s stance follows heightened scrutiny after a 2012 fungal meningitis outbreak linked to contaminated compounding injections.

"The scientific staff has serious safety concerns and will not support a regulation deeming these peptides safe," said one FDA official involved in the discussions.

The HHS draft also includes requirements for pharmacies to source peptide ingredients from FDA-registered facilities and to report adverse events, reflecting the agency’s effort to balance industry interests with consumer safety.

Sigue leyendo, gratis

Crea una cuenta gratis para seguir las noticias. No se requiere tarjeta.